Last reviewed 2026-04-20 · How we verify

MBX-8025

At a glance

Approved indications

No approved indications tracked.

Common side effects

• Pruritus
• Diarrhoea
• Nausea
• Nasopharyngitis
• Abdominal pain
• Abdominal pain upper
• Dyspepsia
• Vomiting
• Fatigue
• Back pain
• Paraesthesia
• Dry eye

Key clinical trials

• Study of Seladelpar in Participants With Primary Biliary Cholangitis (PBC) (PHASE3)
• Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC) (PHASE2)
• A Study to Evaluate the Safety, and Tolerability, and Efficacy of Seladelpar in Patients With PSC (PHASE2)
• A Study to Evaluate Seladelpar in Subjects With Nonalcoholic Steatohepatitis (NASH) (PHASE2)
• Seladelpar (MBX-8025) in Subjects With Primary Biliary Cholangitis (PBC) (PHASE2)
• Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of Seladelpar in Subjects With Hepatic Impairment and Healthy Subjects (PHASE1)
• Study to Evaluate the Effects of MBX-8025 in Patients With HoFH (PHASE2)
• Safety and Benefit of MBX-8025 With and Without Commonly Used Statins in Moderately Overweight Patients With High Cholesterol (PHASE2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• MBX-8025 CI brief — competitive landscape report
• MBX-8025 updates RSS · CI watch RSS
• Gilead Sciences portfolio CI